Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Example investigational product: donor-derived allogeneic NK cells engineered to recognize both MSLN-positive tumor cells and FAPpositive stromal elements, manufactured under GMP”In the company’s words, NCT07510815 on ClinicalTrials.gov
- Tested for
- Malignant Pleural Mesotheliomas
- Main trialPhase 1/2
- “This example study evaluates locoregional allogeneic dual-target mesothelin/FAP CAR-NK cells in adults with unresectable, recurrent, or refractory pleural or peritoneal mesothelioma. Eligible participants must have central confirmation of MSLN-positive tumor cells and FAP-positive tumorassociated stroma. The phase 1 portion defines the recommended phase 2 dose and schedule, and the phase 2 expansion explores preliminary antitumor activity, persistence, and biomarker response in pleural and peritoneal disease cohorts.”In the company’s words, NCT07510815 on ClinicalTrials.gov
- Other names
- Mesothelin/FAP Dual-Target CAR-NK Cells
Other drugs for Malignant Pleural Mesotheliomas
- VT3989Vivace Therapeutics, Inc · Phase 3
- VolrustomigAstraZeneca · Phase 3
- ISM6331InSilico Medicine Hong Kong Limited · Phase 1/2
- Alintegimod7 Hills Pharma, LLC · Phase 1/2
- TYK-01054TYK Medicines · Phase 1/2
- A2B543A2 Biotherapeutics Inc. · Phase 1/2
Coming up1
- 14 Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 14 Mar 2027 | Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026